e-therapeutics shares update on AMD candidate ETX-407
The company noted that its GalOmic pipeline includes ETX-407 for the treatment of dry age-related macular degeneration (AMD).
(Image credit: AdobeStock/Pastel)
e-therapeutics plc, shared business updates across a variety of areas. Among these updates, the company noted that its GalOmic pipeline includes ETX-407 for the treatment of dry age-related macular degeneration (AMD). In the press release1, this stage of development is described as “ETX-407 is continuing to progress through the initial phase of IND-enabling studies, following a stage-gated approach to ensure the efficient use of capital.”
Ali Mortazavi, CEO, of the company commented on the overall progress of the therapeutic pipeline in the press release1, saying, “We continue to make strong and rapid progress towards becoming a clinical-stage biotech company, as we advance our pipeline of novel GalOmic therapies, aiming to file our first IND submission in 2025. I am also excited about the ongoing evolution of HepNet. Our investment in AWS infrastructure demonstrates our commitment to integrating cutting-edge technologies across our platform.”
In addition to the company’s developing pipeline, progress is being made in several other areas, including infrastructure development, application of latest artificial intelligence, expanding our leadership team, strengthening the board, and several noted financial highlights.1
